## Welcome
Welcome to the January 2017 edition of the Area Drug and Therapeutics Committee (ADTC) Collaborative newsletter.

It’s been a busy few months for the ADTC Collaborative and we’re pleased to share some of the work that we’ve undertaken recently.

Previous editions of our bi-monthly newsletters are available on the Healthcare Improvement Scotland website at http://ow.ly/lT7m308kFzm

If you’d like to get in touch, please email [hcis.adtc-collaborative@nhs.net](mailto:hcis.adtc-collaborative@nhs.net)

Sharon Pfleger  
National Clinical Lead

## Support for IPTR and PACS Review

The Montgomery Review recommended the development and implementation of national datasets and definitions for Individual Patient Treatment Request (IPTR) and Peer Approved Clinical Systems (PACS) processes.

The ADTC Collaborative is working with ADTCs to map IPTR and PACS processes across Scotland to support ADTCs and the Scottish Government with future planning.

## ‘Will my medicine make me better? Improving outcomes for people in Scotland’

Nearly 200 delegates joined the ADTC Collaborative at our recent conference to share learning on improving outcomes with medicines.

Delegates heard speakers drawn from across the NHS, the Scottish Government, academia, and the third sector.

The programme featured workshops on shared decision making and measuring patient reported outcomes. Better use of data for patient safety, reducing unwarranted variation and integrating health and social care also featured.

You can download conference slides at [http://ow.ly/oXce308wexM](http://ow.ly/oXce308wexM)

## SMC Collaboration on Off-patent Medicines

The Scottish Medicines Consortium (SMC) and the ADTC Collaborative are undertaking joint working on off-patent medicines. Off-patent medicines are outside the SMC’s health technology assessment remit.

The ADTC Collaborative and SMC are considering ways to assess these medicines and establish the need for guidance and consensus statements.

This work should improve value in the procurement of off-patent medicines within NHSScotland and provide clarity for ADTCs on the cost effectiveness of these medicines and their place in therapy.

## Revised National Guidance on Hepatitis C Medicines

We recently carried out a review of the National Clinical Guidelines for the treatment of HCV in adults, in partnership with National Procurement.

The revised guidance has driven down the price of Hepatitis C medicines further, meaning better value for the NHS and more patients able to access a cure for Hepatitis C.

The guidance is available to download at [http://ow.ly/x8FR308kH8l](http://ow.ly/x8FR308kH8l)
The ADTC Collaborative has developed a new standard formulary template to support open and transparent decision making in NHS boards. The standard formulary template has been circulated to NHS boards and is available to download from http://ow.ly/Gex3308kGxV.

### National Procurement Study Day

ADTC Collaborative Clinical Advisers, Jill Booth and Roy Foot, spoke at the NHSScotland National Procurement study day on 31 January. They covered purpose, function and membership of ADTCs and NHS board formulary management.

The talk was part of a day long programme of learning that supported National Procurement and NHS board staff to understand how new medicines are accepted for use in NHSScotland and how decisions are made within health boards on a medicine’s place in therapy.

### ADTC Self-assessment Framework

A new self-assessment framework for ADTCs is being developed by the ADTC Collaborative in response to a request for future work at October’s ADTC Chairs’ and professional secretaries’ WebEx.

The framework will assist ADTCs to assess how they are addressing medicines governance issues at NHS board level. Look out for the consultation and more information on the framework coming soon.

### DOACs Consensus Statement

The ADTC Collaborative is working with the Effective Prescribing Programme on a potential consensus statement for the use of directly acting anticoagulants (DOACs).

An expert panel on DOACs is in place and clinical engagement will be starting shortly. We will be contacting ADTCs for their feedback in due course.

### Formulary Network

Following the first successful formulary network meeting in October, the ADTC Collaborative facilitated a second meeting in January.

On the agenda were the terms of reference, the Montgomery Review on access to new medicines and an update from Scottish Medicines Consortium, Scottish Government, Effective Prescribing Programme and National Procurement.

The Network will be an essential partner in taking forward the Scottish Government plan to have a single formulary by 2019.

The Network is multidisciplinary and is open to all practitioners with active involvement in formulary development, management and implementation.

The plan is to have two stakeholder meetings each year with key partners to ensure joined up working, in addition to two or three meetings of Network members only. WebEx is available for all meetings.

If you would like to join, please contact us at hcis.adtc-collaborative@nhs.net.

### Medicines Information for Patients and the Public

Our publication, Medicines in Scotland: What’s the right treatment for you?, launched in June 2016, is currently being evaluated by Robert Gordon University.

We recently invited comments on the draft of a follow-on leaflet, focusing on the benefits and risks of medicines, to help patients and healthcare professionals improve shared decision making.

Thank you to everyone who provided comments on the draft document. The feedback was very useful.

There were a number of comments about the overlap of content with the medicines factsheet. The ADTC Collaborative is, therefore, working on merging the two documents into one single leaflet. Based on the feedback, we are also exploring developing an A4 summary of the leaflet and a video.

The leaflet will be published in the Spring.